Viruses viral particles

Hepatitis A vaccine exemplifies vaccine preparations containing inactivated viral particles. It consists of a formaldehyde-inactivated preparation of the HM 175 strain of hepatitis A virus. Viral particles are normally propagated initially in human fibroblasts. 

The size of this viral particle is of course larger than that of a virus with only 60 subunits. The diameter of tomato bushy stunt virus is 330 A compared with 180 A for satellite tobacco necrosis virus. The increase in volume of the capsid means that a roughly four times larger RNA molecule can be accommodated. 

In contrast to retroviruses, proteolysis is an early event in the replication cycle of (+)-strand RNA viruses and both protease and polymerase inhibitors can be expected to halt the propagation of infectious viral particles from already infected cells. 

Apart from offering a new and highly specific approach to the inhibition of herpesviruses, this new mechanism of action could potentially also have beneficial immunological consequences. During treatment with BAY 38-4766, viral protein synthesis continues, but due to the lack of monomeric genomic length DNA, only empty particles (dense bodies) can be formed. It is conceivable that these non-infections viral particles could aid the establishment of an antiviral immune response, leading to better control of the virus by the host. This mechanism appears... 

Consequences of virus infection in animal cells Viruses can have varied effects on cells. Lytic infection results in the destruction of the host cell. However, there are several other possible effects following viral infection of animal cells. In the case of enveloped viruses, release of the viral particles, which occurs by a kind of budding process, may be slow and the host cell may not be lysed. The cell may remain alive and continue to produce vims over a long period of time. Such infections are referred to as persistent infections. 

Biopharmaceutical products are also subjected to screening for the presence of viral particles prior to final product release. Although viruses could be introduced, for example, via infected personnel during downstream processing, proper implementation of GMP minimizes such risk. Any viral particles found in the finished product are most likely derived from raw material sources. Examples could include HIV or hepatitis viruses present in blood used in the manufacture of blood products. Such raw materials must be screened before processing for the presence of likely viral contaminants. 

Removal of viruses from the product stream can be achieved in a number of ways. The physicochemical properties of viral particles differ greatly from most proteins, ensuring that effective fractionation is automatically achieved by most chromatographic techniques. Gel-filtration chromatography, for example, effectively separates viral particles from most proteins on the basis of differences in size. 

The starting material will likely be contaminated by intact, viable hepatitis B viral particles (and perhaps additional viruses, such as HIV). This necessitates introduction of stringent purification procedures to ensure complete removal of any intact viral particles from the product stream. A final product QC test to confirm this entails a 6-month safety test on chimpanzees. 

The potential of inactivated viral particles as effective vaccines has gained some attention, but again fears of accidental transmission of disease if inactivation methods are not consistently 100 per cent effective have dampened enthusiasm for such an approach. In addition, the stringent containment conditions required to produce large quantities of the virus render such production processes expensive. 

Initial studies using this system have proved encouraging. The altered virus (without associated monoclonal antibody) failed to infect a wide variety of human cell lines. By initially incubating with monoclonal antibody of the appropriate specificity, however, the viral particles were capable of efficiently transducing cells expressing surface receptors such as CD4, CD33 and human leukocyte antigen. 

Fig. 8.3 Cartoon illustrating the alignment of the particles of two different orienting media, a Disc particles represent lipid bicelles. b Rods represent viral particles. Bicelles orient with their normal orthogonal to the magnetic field and viruses with their long axis parallel to it. (Reproduced with permission from N. Tjandra, Structure 1999, 7, R205-R211.)...

The presence of human papilloma virus (HPV) is associated with female genital tract diseases such as condyloma, Bowenoid papulosis, and cervical, vaginal, and vulvar intraepithelial neoplasia and carcinoma. A general concern is the association of HPV with cervical cancer (Gl). The HPV consists of an icosahedral viral particle (virion) containing 8000 base pairs, a circular, double-stranded piece of DNA surrounded by a protein capsid. Viral replication takes place within the nuclei of infected squamous epithelial cells (H5). Following infection of epithelial cells, the viral DNA penetrates throughout the entire thickness of the epithelium, but intact viruses are found only in the upper layers of tissue. 

Reverse transcriptase is an enzyme that makes a DNA copy of the virus RNA (Step 3). Once made, the DNA enters the cell nucleus and rephcates many times. Another enzyme, the protease, is required to cut the HIV proteins into proper sizes and assemble into the viral particles (Step 7). 

These new estimates of the particle weight change the number of copies of the viral glycoprotein per viral particle. The polypeptides (capsid, 1, E2, and 3) are present in equimolar amounts (Garoff et al., 1974). Since 56.6% of the virus is protein (leaving out the carbohydrate content) the viral particle (using a molecular weight of 41-42 x 10 ) should contain about 180 copies of each protein. 

Further confirmation for the location of the membrane-spanning domains of the El and of the E2 polypeptide chains has come from studies of Sindbis virus. After chymotrypsin digestion of the viral particle, the... 

---